Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain
Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain
复制标题
DOI:
10.1186/1742-2094-10-30
复制
发表时间:
2013-02-26
影响因子:
9.3
通讯作者:
Sankar, Raman
中科院分区:
文献类型:
--
作者:
Kwon, Young Se;Pineda, Eduardo;Sankar, Raman
Background: Inflammatory signaling elicited by prolonged seizures can be contributory to neuronal injury as well as adverse plasticity leading to the development of spontaneous recurrent seizures (epilepsy) and associated co-morbidities. In this study, developing rat pups were subjected to lithium-pilocarpine status epilepticus (SE) at 2 and 3 weeks of age to study the effect of anti-inflammatory drugs (AID) on SE-induced hippocampal injury and the development of spontaneous seizures.Findings: We selected AIDs directed against interleukin-1 receptors (IL-1ra), a cyclooxygenase-2 (COX-2) inhibitor (CAY 10404), and an antagonist of microglia activation of caspase-1 (minocycline). Acute injury after SE was studied in the 2-week-old rats 24 h after SE. Development of recurrent spontaneous seizures was studied in 3-week-old rats subjected to SE 4 months after the initial insult.None of those AIDs were effective in attenuating CA1 injury in the 2-week-old pups or in limiting the development of spontaneous seizures in 3-week-old pups when administered individually. When empiric binary combinations of these drugs were tried, the combined targeting of IL-1r and COX-2 resulted in attenuation of acute CA1 injury, as determined 24 h after SE, in those animals. The same combination administered for 10 days following SE in 3-week -old rats, reduced the development of spontaneous recurrent seizures and limited the extent of mossy fiber sprouting.Conclusions: Deployment of an empirically designed 'drug cocktail' targeting multiple inflammatory signaling pathways for a limited duration after an initial insult like SE may provide a practical approach to neuroprotection and anti-epileptogenic therapy.